此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

1 型糖尿病扩展研究 (T1DES)

This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).

This observational study will:

  • follow participants to determine how long they continue to produce insulin, and
  • will also assess how changes in the immune system over time relate to the ability to produce insulin.

This information could help design better therapies for type 1 diabetes in the future.

研究概览

地位

招聘中

详细说明

Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:

  • Overall health assessments
  • Blood and urine collections
  • Mixed meal tolerance test (MMTTs) for certain participants, per protocol.

研究类型

观察性的

注册 (估计的)

111

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • San Francisco、California、美国、94143
        • 招聘中
        • UCSF School of Medicine
        • 接触:
        • 首席研究员:
          • Stephen Gitelman, MD
      • Stanford、California、美国、94305
        • 招聘中
        • Stanford University
        • 接触:
        • 首席研究员:
          • Darrell Wilson, MD
    • Colorado
      • Aurora、Colorado、美国、80045
        • 招聘中
        • University of Colorado School of Medicine: Barbara Davis Center for Diabetes
        • 首席研究员:
          • Peter Gottlieb, MD
        • 接触:
    • Connecticut
      • New Haven、Connecticut、美国、06519
        • 完全的
        • Yale University
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 撤销
        • Emory University
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • 招聘中
        • Indiana University Riley Hospital for Children
        • 接触:
        • 接触:
        • 首席研究员:
          • Linda DiMeglio, MD, MPH
    • Iowa
      • Iowa City、Iowa、美国、52242
        • 招聘中
        • University of Iowa Health Care Division of Pediatric Endocrinology
        • 接触:
        • 首席研究员:
          • Michael Tansey, MD
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Joslin Diabetes Center
        • 接触:
        • 首席研究员:
          • Jason Gaglia, MD
    • Minnesota
      • Minneapolis、Minnesota、美国、55454
        • 招聘中
        • University of Minnesota
        • 接触:
        • 首席研究员:
          • Antoinette Moran, MD
    • Missouri
      • Kansas City、Missouri、美国、64108
        • 完全的
        • Children's Mercy Hospital
    • South Dakota
      • Sioux Falls、South Dakota、美国、57104
        • 完全的
        • Sanford Research
    • Washington
      • Seattle、Washington、美国、98101
        • 招聘中
        • Benaroya Research Institute
        • 首席研究员:
          • Sandra Lord, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

8年 至 35年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus (T1DM) studies with immunomodulatory agents as the intervention.

描述

Inclusion Criteria:

  • Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
  • Ability to sign informed consent/assent (as applicable for children).

Exclusion Criteria:

  • Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
  • Inability to comply with the study visit schedule and required assessments.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Group 1: Detectable C-peptide by MMTT

Participants with detectable C-peptide at their:

  • Last Immune Tolerance Network (ITN) T1DM week 104 study visit,
  • Last AbATE (NCT00129259) follow-up visit, or
  • Last ITN066AI T1DES visit

Detectable C-peptide is defined as a value above the lower limit of detection.

Group 2:Undetectable C-peptide by MMTT

Participants without detectable C-peptide at their:

  • Last ITN T1DM week 104 study visit,
  • Last AbATE follow-up visit, or last
  • ITN066AI T1DES visit

Undetectable C-peptide is defined as a value below the lower limit of detection.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)
大体时间:Baseline (Visit 0) to Month 60 (Year 5)

Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC).

C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin.

Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL.

Baseline (Visit 0) to Month 60 (Year 5)

次要结果测量

结果测量
措施说明
大体时间
Change in Insulin Use in Units per Kilogram Body Weight Per Day
大体时间:Baseline (Visit 0) to Month 60 (Year 5)

The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity.

Baseline (Visit 0) to Month 60 (Year 5)
Change in HbA1C
大体时间:Baseline (Visit 0) to Month 60 (Year 5)

Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease.

Baseline (Visit 0) to Month 60 (Year 5)
Count of Participant-Reported Major Hypoglycemic Events
大体时间:Baseline (Visit 0) to Month 60 (Year 5)

Major hypoglycemic events are defined as a glucose concentration <55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover.

Baseline (Visit 0) to Month 60 (Year 5)
Time to Undetectable C-Peptide
大体时间:Baseline (Visit 0) to Month 60 (Year 5)

To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates.

Baseline (Visit 0) to Month 60 (Year 5)
Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest
大体时间:Baseline (Visit 0) to Month 60 (Year 5)

Events of interest include but are not limited to:

  • Opportunistic and serious infections
  • Malignancy
  • Cardiovascular disease
  • Development of autoimmune disease(s)
  • Hypersensitivity reactions to unrelated allergens

Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010).

Baseline (Visit 0) to Month 60 (Year 5)
Severity of Grade 3 or Higher Adverse Events (AEs) of Interest
大体时间:Baseline (Visit 0) to Month 60 (Year 5)

Events of interest include but are not limited to:

  • Opportunistic and serious infections
  • Malignancy
  • Cardiovascular disease
  • Development of autoimmune disease(s)
  • Hypersensitivity reactions to unrelated allergens

Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010).

Baseline (Visit 0) to Month 60 (Year 5)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Linda A. DiMeglio, MD, MPH,MA、Riley Hospital for Children at Indiana University Health

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年6月8日

初级完成 (估计的)

2028年8月1日

研究完成 (估计的)

2028年8月1日

研究注册日期

首次提交

2016年4月6日

首先提交符合 QC 标准的

2016年4月6日

首次发布 (估计的)

2016年4月12日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月15日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.

IPD 共享时间框架

After completion of the study.

IPD 共享访问标准

Will be available to the public.

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅